NCT01699555View on ClinicalTrials.gov

First-in-Human Study With GNbAC1 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

August 31, 2012

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

GNbAC1

Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg

BIOLOGICAL

GNbAC1 placebo

Single dose intravenous (IV) GNbAC1 placebo

Sponsors
All Listed Sponsors
lead

GeNeuro Innovation SAS

INDUSTRY